Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 P/E Ratio

The latest P/E ratio for HROWL is -33.33. That is below the Healthcare sector average of 25.3. Investors often review this figure alongside Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, HROWL currently prints -33.33 for P/E ratio, while the sector average sits near 25.3. That is roughly 231.8% below the sector mean. Large gaps often invite a closer look at Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's growth, margins, and balance sheet.

A P/E ratio of -33.33 for Harrow- 8.625% NT REDEEM 30/04/2026 USD 25 is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with HROWL's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting HROWL's P/E ratio (-33.33), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Harrow- 8.625% NT REDEEM 30/04/2026 USD 25's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.